Reference : Update on therapy of relapsed and refractory multiple myeloma
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/225860
Update on therapy of relapsed and refractory multiple myeloma
English
Vekemans, M-C. []
Beel, K. []
CAERS, Jo mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique >]
Meuleman, N. []
Bries, G. []
Demuynck, H. []
DE PRIJCK, Bernard mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique >]
De Samblanx, H. []
Deweweirea, A. []
Fostier, K. []
Mineur, P. []
Vaes, M. []
Vande Broeck, I. []
Vande Velde, A. []
Van Droogenbroeck, J. []
Vlummers, P. []
Wu, K-L. []
Schots, R. []
Delforge, M. []
Doyen, C. []
2017
Belgian Journal of Hematology
Ariez Medical Publishing
8
53-65
Yes (verified by ORBi)
International
2033-3749
Amsterdam
Netherlands
[en] novel drugs ; relapsed and refractory myeloma ; salvage chemotherapy
[en] The prognosis for multiple myeloma patients has improved substantially over the past decade with the development of more effective chemotherapeutic agents and regimens that possess a high level of anti-tumour activity.
However, nearly all multiple myeloma patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed disease remains a critical aspect of multiple myeloma care and an important area of ongoing research. This manuscript from the Belgian Haematology Society multiple myeloma subgroup provides some recommendations on the management of relapsed disease.
http://hdl.handle.net/2268/225860

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
bjh_2017_8-2-53-65.pdfPublisher postprint313.78 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.